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Abstract
Background: Association between high body mass index (BMI) and survival benefit is confounded by comorbid
conditions such as nutritional status and inflammation. Patients with acute kidney injury (AKI), particularly those
receiving continuous renal replacement therapy (CRRT), are highly catabolic and more susceptible to loss of energy.
Herein, we evaluated whether disease severity can modify the relationship between BMI and mortality.
Methods: We conducted an observational study in 1144 patients who had undergone CRRT owing to various
causes of AKI between 2010 and 2014. Patients were categorized into four groups; underweight (< 18.5 kg/m2),
normal (18.5–22.99 kg/m2), overweight (23.0–24.99 kg/m2), and obesity (≥25 kg/m2) according to BMI classification by
the Committee of Clinical Practice Guidelines and Korean Society for the Study of Obesity. More severe disease was
defined as sepsis-related organ failure assessment (SOFA) score of ≥ a median value of 12. The study endpoint was death
that occurred within 30 days after the initiation of CRRT.
Results: The mean age was 63.2 years and 439 (38.4%) were females. The median BMI was 23.6 (20.9–26.2) kg/m2. The
obese group were younger and higher SOFA score than normal BMI group. In a multivariable Cox regression analysis, we
found a significant interaction between BMI and SOFA score (P < 0.001). Furthermore, obese patients were significantly
associated with a lower risk of death as compared to normal BMI group after adjusting confounding factors [hazard ratio
(HR), 0.81; 95% confidence interval (CI), 0.68–0.97; P = 0.03]. This association was only evident among patients with high
severity (HR, 0.61; 95% CI, 0.48–0.76, P < 0.001). In contrast, in those with low severity, survival benefit of high BMI was lost,
whereas underweight was associated with an increased risk of death (HR, 1.74; 95% CI, 1.16–2.60; P = 0.007).
Conclusion: In this study, we found a survival benefit of high BMI in AKI patients undergoing CRRT, particularly in those
with more disease severity; the effect was not observed in those with less disease severity.
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Background
Obesity has recently emerged as an important public health
problem worldwide. It is indeed associated with hyperten-
sion, dyslipidaemia, and diabetes mellitus (DM) and obese
individuals who have these comorbid conditions are at a
high risk of developing cardiovascular and cerebrovascular
diseases [1]. Obesity is also highly associated with the devel-
opment of chronic kidney disease (CKD), microalbumi-
nuria, and overt proteinuria [2]. Interestingly, obesity is
commonly observed in many critically ill patients who are
admitted to the intensive care unit (ICU). In a previous
meta-analysis from the United States, approximately 30% of
ICU patients had a body mass index (BMI) of ≥30 kg/m2,
and duration of mechanical ventilation and length of ICU
stay were longer in these patients [3].
Acute kidney injury (AKI) commonly occurs and is a
serious problem especially in critically ill patients because
complications caused by AKI can lead to adverse outcomes
such as increased length of hospital stay, high mortality, and
progression to CKD [4]. Because obese patients are burdened
with high comorbidities, they are more likely to develop AKI
and suffer from more serious complications than non-obese
patients. However, there has been conflicting results on the
association between AKI, obesity, and mortality. In fact, pre-
vious studies have shown that obese patients had high inci-
dence of AKI and more severe kidney injury [5–8], resulting
in increased mortality [6, 9, 10]. Nevertheless, there have been
several reports that obesity exhibited an inverse or null rela-
tionship with mortality [5, 11–15]. In fact, some recent stud-
ies clearly showed that critically ill patients with obesity have
survival benefit while they are treated in the ICU [7, 16].
One possible mechanism of obesity paradox is that high
nutritional reserve of obese patients plays an important
role during acute life-threatening illness [17]. Interestingly,
recent observational studies reported that the relationship
between obesity and mortality is confounded by comorbid
conditions. In these studies, survival benefit of obese
patients was observed only in patients with high C-
reactive protein (CRP), but not in those with low CRP
[18]. In addition, among patients with obesity, malnour-
ished patients had worse outcomes than those in relatively
good nutritional status [19]. Of note, patients with AKI
are more likely to have high comorbidities and high
disease severity. In particular, these patients are highly
inflamed and deprived of nutrition because of increased
protein catabolism and high energy consumption. This
process can be more deteriorated when disease severity is
high. Thus, we hypothesized that survival benefit of obes-
ity is more evident under high disease severity condition.
In this study, we sought to examine whether disease
severity can modify the relationship between obesity and
mortality in critically ill patients and conducted an obser-
vational study in patients with AKI who underwent
continuous renal replacement therapy (CRRT).
Methods
Patient selection
This study retrospectively examined the relationship
between body mass index and mortality by disease severity.
Figure 1 presents a flow chart depicting the selection of
subjects. We selected 1144 adult patients who were treated
with CRRT in the ICU at two medical centers, Yonsei
University Severance Hospital and National Health
Insurance Service Medical Center Ilsan hospital between
January 2010 and December 2014. Among 2391 patients
who were initially assessed for study eligibility, 1247
patients who met following criteria were excluded: 1) ≤18
or ≥75 years old, 2) end-stage renal disease (ESRD) on
dialysis, 3) stage 4 malignancy, or 4) no data for BMI. The
study was approved by the Institutional Review Board (IRB)
of each center. Since current study was a retrospective
observational study and the study subjected de-identified,
the IRB waived the need for written consent from the
patients.
Data collection
We reviewed electronic medical records and collected
demographic and laboratory data. BMI was determined
based on the formula of weight (kg)/height (m2). Weight
and height of all patients were measured upon ICU admis-
sion. To evaluate the severity of the patients’ comorbidities,
Fig. 1 Flowchart of participants in the cohort. Abbreviations: AKI, acute
kidney injury; ESRD, end stage renal disease; BMI, body mass index
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the Charlson comorbidity index (CCI) was calculated by
using the score system as previously proposed [20]. Blood
tests were done immediately after ICU admission and used
for baseline data. The measured laboratory data included
white blood cell (WBC) count, haemoglobin, haematocrit,
platelet, prothrombin time, partial thromboplastin time,
CRP, cholesterol, albumin, blood urea nitrogen, and creatin-
ine. The Modification of Diet in Renal Disease equation
[21] was used to determine the baseline estimated glomeru-
lar filtration rate (eGFR). The sepsis-related organ failure
assessment (SOFA) score and Acute Physiology and
Chronic Health Evaluation (APACHE) II score were also
calculated based on data for the average vital signs, PaO2,
FiO2, and Glasgow coma scale score in the first 24 h of
ICU admission.
CRRT protocol
Upon the development of AKI in ICU patients, nephrolo-
gists intervened and decided whether or not to begin CRRT
in those who were critically ill. Generally, CRRT was applied
in patients with sustained oliguria, uncontrolled volume
overload, hyperkalemia or metabolic acidosis. All patients
received continuous veno-venous haemodiafiltration by
using a Prisma (Gambro Co., Ltd., Hechingen, Germany),
Prismaflex (Gambro Co., Ltd), or multiFiltrate (Fresenius
Medical Care GmbH, Bad Homburg, Germany) machine,
through the internal jugular, subclavian, or femoral vein.
CRRT machines were installed, and the system was main-
tained by trained and educated nurses. Biocompatible
polyethersulphone membranes were used in all CRRTs. Pre--
filter replacement was loaded with bicarbonate-containing
fluid, and a pre-dilution method was applied. CRRT was
started at a blood flow rate of 100 mL/min, and this was in-
creased up to 150 mL/min. The total effluent volume as a
sum of dialysis and replacement dose was targeted to deliver
≥35 mL⋅kg− 1⋅h− 1 in all patients.
Definition
According to the World Health Organization (WHO) BMI
classification, the criteria for obesity and overweight are
≥30 kg/m2 and ≥25 kg/m2, respectively. However, these
cut-off values can be lowered for Asian populations. The
prevalence of obesity in Asians by the conventional criteria
is much lower and Asians confront higher metabolic risk
even under BMI of 30 kg/m2 compare to other ethnic
groups [22]. In fact, Korean individuals with a BMI of 23 to
24.9 kg/m2 are at higher risk of type 2 diabetes and hyper-
tension as compared to those within the normal BMI
range. Therefore in 2014, the Committee of Clinical
Practice Guidelines and Korean Society for the Study of
Obesity [23] proposed BMI classification as follows; under-
weight (< 18.5 kg/m2), normal (18.5–22.99 kg/m2), over-
weight (23.0–24.99 kg/m2), and obesity (≥25 kg/m2). In this
study, we followed these criteria to define obesity. In
addition, disease severity was assessed by using SOFA
score. More severe disease was defined as SOFA score ≥ a
median value of 12.
Primary outcome
The primary outcome was overall survival measured from
the date of the initiation of CRRT until death or day 30.
Statistical analyses
Continuous variables were expressed as mean ± SD, and
compared with t-test and one-way ANOVA. To compare
between subgroups, post-hoc analysis was performed with
Bonferroni analysis. The normality of the distribution of
parameters was analysed by using the Kolmogorov-
Smirnov test. If data did not show a normal distribution,
these were presented as median and interquartile range
and compared by using the Mann–Whitney test or
Kruskal–Wallis test. Categorical variables were expressed
as percentages and compared with the chi-square test.
To evaluate the relationship of BMI with covariables,
and mortality, multivariable-adjusted Cox-proportional
hazard models were constructed, and the results were
presented as a hazard ratio (HR) and 95% confidence
interval (CI). In model 1, we entered age, sex, CCI score,
septic AKI, mean arterial pressure (MAP), eGFR, and
SOFA score. We additionally adjusted WBC and
albumin as an inflammatory marker and a nutritional
marker, respectively, in model 2, and CRRT prescription
was further added in model 3. To evaluate the impact of
disease severity on the relationship between BMI and
mortality, we first examined interaction between BMI
and SOFA score in Cox proportional hazard models.
Then, the same analyses were performed according to
disease severity status and presence of comorbidities.
In sensitivity analyses, we re-categorized patients by
another BMI criteria. The WHO recommends that
additional cut-off points of obesity such as 23, 27.5, 32.5
and 37.5 kg/m2 can be used for public health action [24].
Thus, we applied these criteria to confirm our findings.
Furthermore, we re-defined disease severity according to
APACHE II score. The high disease severity was defined
as APACHE II score of ≥ a median value of 28, and Cox
regression analyses were repeated after switching SOFA
score to APACHE II score. Finally, we performed
restricted cubic splines to examine whether the associ-
ation between disease severity and mortality may differ de-
pending on the presence of obesity. Statistical significance
was defined as P < 0.05. All analyses were conducted by
using SPSS, version 23.0 (IBM Corporation, Armonk, NY,
USA), SAS version 9.4 (SAS Institute, Cary, NC, USA),
and GraphPad Prism version 5.0 (GraphPad Software Inc.,
San Diego, CA, USA).
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Results
Patient characteristics
The baseline characteristics of the patients according to
BMI are presented in Table 1. The mean age was 63.2 years,
and 439 patients (38.4%) were women. The obese group
was younger than normal (P = 0.02) and overweight group
(P = 0.02). The average BMI was 23.6 (20.9–26.3) kg/m2.
The mean CCI score was 3.2 ± 2.2 and was similar between
groups. Sepsis was a predominant cause of ICU admission
and 797 patients (69.7%) had undergone sepsis. The most
common cause of CRRT was sustained oliguria and did not
different between groups. The dose of CRRT was 43.4 ±
16.9 mL/kg and obese group received significantly lower
CRRT dose than underweight (P = 0.006) and normal group
(P < 0.001). The average SOFA and APACHE II score were
12.1 ± 3.6 and 27.1 ± 8.4, respectively. The SOFA score was
significantly higher in obese group than in underweight (P
= 0.02) and normal group (P = 0.03); however, APACHE II
score did not differ between groups (P = 0.44). The baseline
characteristics according to disease severity are presented
in Table 2. BMI was significantly higher in the high severity
group than in the low severity group [23.4 (20.8–25.9) vs.
23.9 (21.2–26.7) kg/m2, P = 0.009]. The patients in the low
disease severity group had higher prevalence of DM and
cardiovascular disease, whereas cancer was more prevalent
in the high severity group. As a result, the low severity
group had a significantly lower CCI score than the higher
severity group (P = 0.002). In addition, eGFR and the level
of total cholesterol and hemoglobin were lower in the high
severity group than in the low severity group. As expected,
percentages of patients treated with vasopressor and
mechanical ventilation were significantly higher in the high
severity group than in the lower severity group (P < 0.001,
respectively).
ICU and hospital stay durations and mortality rates
according to BMI classification
Table 3 shows the ICU and hospital stay durations,
survival days, and 30-day mortality rates. The mean ICU
and hospital stay was 8 (3–17.5) and 20 (6–43) days, re-
spectively. Among patients with high severity, the length
of hospital stay was longer in the higher BMI groups
than in the underweight group, whereas both ICU and
hospital stay were longer in the normal BMI group than
others, among those with low severity. During 30 days
after CRRT initiation, a total of 701 deaths (61.3%)
occurred. The mortality in the obese group was 56.8%,
which was significantly lower than in the underweight
group (70.7%, P = 0.01). Among those with high disease
severity, obese group had a significantly lower 30th day
mortality than the normal (P < 0.001) and underweight
group (P = 0.007). However, this trend was attenuated in
patients with low disease severity (P = 0.06).
Relationship between BMI and mortality by disease
severity in multivariable-adjusted models
The association between BMI and mortality was further
analyzed using multivariable-adjusted Cox models. To this
end, we constructed four different models (Table 4). Over-
all, obesity was significantly associated with a decreased risk
of 30-day mortality in the fully adjusted model (HR, 0.81;
95% CI, 0.68–0.97; P = 0.03). In addition, survival benefit of
high BMI was also observed when BMI was treated as a
continuous variable (HR, 0.97 per 1 kg/m2 increase; 95%
CI, 0.96–0.99; P < 0.001). Notably, the underweight group
was associated with an increased risk of death, but it did
not reach statistical significance. As mentioned earlier, the
relationship between BMI and mortality is confounded by
comorbidity conditions. Therefore, we checked an inter-
action between BMI and disease severity using Cox regres-
sion analysis. When the interaction term was included, we
found there was a significant interaction between BMI and
SOFA score (P < 0.001), suggesting the relationship
between BMI and mortality was affected by disease severity.
Thus, we further analyzed this association in depth accord-
ing to disease severity (Table 4 and Fig. 2). Among patients
with low severity, the underweight patients were at higher
risk of 30-day mortality (HR, 1.74; 95% CI, 1.16–2.60; P =
0.007) than the normal group. In addition, the overweight
and the obese groups also had an increased risk of death as
compared with the normal group, resulting in U-shaped
risk pattern, although it did not reach the statistical signifi-
cance in the obese group. In contrast, among those with
high severity, obesity was significantly associated with a
decreased risk of 30-day mortality (HR, 0.61; 95% CI, 0.48–
0.76; P < 0.001) as compared with the normal BMI. How-
ever, risk of death did not increase in the underweight and
the overweight groups. When BMI was analyzed as a con-
tinuous variable, high BMI was independently associated
with a decreased risk of death only in the high severity
group (HR, 0.96 per 1 kg/m2 increase; 95% CI, 0.94–0.98;
P < 0.001), but not in the low severity group.
Sensitivity analyses
To confirm our findings, we further analyzed in four
groups categorized according to BMI of < 18.50 (under-
weight), 18.50–24.99 (normal), 25.00–27.49 (overweight),
and ≥27.5 (obesity) kg/m2. In agreement with the findings
in Table 4, the association between BMI and mortality by
disease severity remained the same after full adjustment of
confounders (Additional file 1: Table S1). Furthermore,
when we re-defined higher disease severity as APACHE II
score of ≥28, survival benefit of obesity was observed only
in the high severity group. (Additional file 2: Table S2).
This finding was more evidenced by cubic spline curves.
The results showed that disease severity assessed by SOFA
score was significantly associated with mortality only in
Kim et al. BMC Nephrology  (2018) 19:32 Page 4 of 10
Table 1 Baseline characteristics of patients according to BMI classification
BMI classification Total p-value
Underweight Normal Overweight Obesity
Number 99 403 220 422 1144
BMI (kg/m2)a 16.9 (15–17.8) 21.1 (20.1–22.2) 24.1 (13.5–24.5) 27.5 (25.9–29.2) 23.6 (20.9–26.3) < 0.001
Age (yr) 62.3 ± 17.2 65.0 ± 13.6 63.9 ± 14.0 61.3 ± 14.5 63.2 ± 14.4 0.002
Sex (Female, %) 38 (38.4) 162 (40.2) 65 (29.5) 174 (41.3) 439 (38.4) 0.03
DM (n, %) 27 (27.6) 140 (34.7) 79 (35.9) 153 (36.3) 399 (34.9) 0.42
HTN (n, %) 40 (40.4) 217 (53.8) 110 (50.0) 233 (55.3) 600 (52.5) 0.05
MI (n, %) 10 (10.1) 47 (11.7) 17 (7.7) 37 (8.8) 111 (9.7) 0.37
CHF (n, %) 20 (20.2) 71 (17.6) 37 (16.8) 57 (13.5) 185 (16.2) 0.26
CVA (n, %) 7 (7.1) 50 (12.4) 25 (11.4) 35 (8.3) 117 (10.2) 0.08
PVD (n, %) 6 (6.1) 15 (3.7) 12 (5.5) 13 (3.1) 46 (4.0) 0.35
COPD (n, %) 11 (11.0) 33 (8.2) 13 (5.9) 23 (5.5) 80 (7.0) 0.15
Cancer (n, %)
Solid tumor 18 (18.4) 96 (23.8) 51 (23.3) 93 (22.1) 258 (22.6)
Metastasis 5 (5.1) 19 (4.7) 18 (8.2) 26 (6.2) 68 (6.0) 0.77
Leukemia 3 (3.1) 19 (4.7) 13 (5.9) 16 (3.8) 51 (4.5)
Lymphoma 12 (12.2) 37 (9.2) 21 (9.6) 38 (9.0) 108 (9.5)
CCI score 3.1 ± 2.4 3.2 ± 2.2 3.1 ± 2.2 3.2 ± 2.3 3.2 ± 2.2 0.94
Sepsis (n, %) 74 (74.7) 294 (73.0) 149 (67.7) 280 (66.5) 797 (69.7%) 0.13
Postop AKI (n, %) 3 (3.0) 13 (3.2) 9 (4.1) 26 (6.2) 51 (4.5) 0.18
Cause of CRRT
Volume overload 8 (8.1) 62 (15.3) 26 (11.8) 64 (15.2) 160 (13.9)
Metabolic acidosis 26 (26.3) 85 (21.1) 43 (19.5) 88 (20.8) 242 (21.2)
Hyperkalemia 2 (2.0) 19 (4.7) 12 (5.4) 25 (5.9) 58 (5.1) 0.86
Uremia 13 (13.1) 35 (8.7) 21 (9.5) 46 (10.9) 115 (10.1)
Oliguria 35 (35.4) 112 (27.5) 54 (24.5) 93 (22.0) 294 (25.7)
Others 15 (15.2) 90 (22.4) 64 (29.1) 106 (25.1) 275 (24.0)
CRRT dose (mL/kg) 46.2 ± 16.4 44.6 ± 19.4 41.3 ± 15.1 40.0 ± 15.0 43.4 ± 16.9 < 0.001
MAP (mmHg) 76.6 ± 17.5 77.4 ± 14.2 77.3 ± 14.3 77.7 ± 14.5 77.5 ± 14.6 0.92
Creatinine (mg/dL) 2.6 ± 1.5 2.5 ± 1.3 2.9 ± 1.9 2.9 ± 1.7 2.7 ± 1.6 0.001
eGFR (mL/min/1.73m2) 33.2 ± 18.0 33.1 ± 22.3 32.7 ± 24.4 29.0 ± 18.8 31.5 ± 21.4 0.03
Albumin (g/dL) 2.5 ± 0.5 2.6 ± 0.6 2.6 ± 0.6 2.6 ± 0.6 2.6 ± 0.6 0.47
Total cholesterol (mg/dL) 111.9 ± 55.9 107.6 ± 48.5 98.1 ± 46.5 108.1 ± 68.9 106.2 ± 57.3 0.56
WBC (× 103/mm3) 15.3 ± 25.9 13.8 ± 11.7 14.7 ± 12.8 13.7 ± 9.9 14.1 ± 13.2 0.64
Hemoglobin (g/dL) 9.7 ± 2.4 9.7 ± 2.1 9.4 ± 2.4 9.6 ± 2.3 9.6 ± 2.3 0.56
CRP (mg/L)a 37.1 (10.6–213.8) 87.3 (17.7–171.7) 72.9 (18.6–255.7) 56.7 (14.2–151.8) 67.5 (15.4–164.1) 0.06
Vasopressor (n, %) 68 (68.9) 270 (67.0) 165 (75.3) 314 (74.4) 817 (71.4) 0.15
Ventilator (n, %) 80 (81.0) 345 (85.7) 184 (83.7) 352 (83.5) 961 (84.0) 0.74
SOFA 11.3 ± 3.4 11.8 ± 3.7 12.0 ± 3.5 12.5 ± 3.5 12.1 ± 3.6 0.005
APACHE II 26.4 ± 8.3 27.4 ± 8.0 27.5 ± 9.1 26.7 ± 8.4 27.1 ± 8.4 0.44
Abbreviations: DM diabetes mellitus, HTN hypertension, MI myocardiac infarction, CHF congestive heart failure, CVA cerebrovascular attack, PVD peripheral vascular
disease, COPD chronic obstructive pulmonary disease, CCI Charlson comorbidity index, AKI acute kidney injury, BMI body mass index, MAP mean arterial pressure,
eGFR estimated glomerular filtration rate, WBC white blood cell, SOFA sepsis-related organ failure assessment
aData were expressed as a median and interquartile range and compared by Kruskal-Wallis test
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non-obese patients, whereas this association was lost in
obese patients (Additional file 3: Figure S1).
Subgroup analyses on the relationship between BMI and
mortality according to disease severity
We further analyzed the impact of disease severity on the
association between BMI and mortality in several sub-
groups (Fig. 3), which were stratified by age, sex, diabetes,
cardiovascular disease, and cancer. In Cox regression
models after full adjustment and BMI as a continuous
variable, trends toward a decreased risk of death in high
BMI were consistently observed across the subgroups.
Discussion
In this study, we showed the different relationships
between BMI and mortality according to the disease
severity in AKI patients undergoing CRRT. Using different
multivariable-adjusted models, we found a U-shaped risk
pattern of mortality in the low severity group, whereas
survival advantage of high BMI was consistently observed
in the high severity group. Thus, our findings suggest that
disease severity can modify the recently prevailing concept
of the “obesity paradox” in critically ill patients undergo-
ing continuous renal replacement therapy.
Previous meta-analyses and observational studies involv-
ing a large number of ICU patients have suggested that
patients with a higher BMI are more likely to survive than
those with a lower BMI [13, 16, 17]. We particularly paid
attention to patients with AKI requiring CRRT. Critically ill
patients are generally hypercatabolic and have substantial
energy expenditure in proportion to high level of stress [25,
26]. In addition, patients with AKI have a high prevalence
of malnutrition [27], and protein is excessively degraded by
AKI-induced uraemia [28]. Notably, loss of protein is accel-
erated in AKI patients undergoing CRRT because protein
and other nutritional elements are lost through CRRT [29].
It was also found that centrally infused protein losses into
CRRT effluent range from 10 to 17% [30–32]. In this
regard, AKI patients on CRRT are more susceptible to a
loss of energy reserve. The unique characteristics of these
patients can explain why high BMI provided survival
advantage in patients with high disease severity.
Conversely, high BMI itself has been considered as a
significant risk factor of AKI. A recent observational
cohort studies found that obese patients were at a higher
risk of developing AKI than patients with normal BMI
[6, 7]. Interestingly, BMI plays a different role in acutely
ill patients after having AKI. In a study by Druml et al.
[7] involving 5232 patients with ‘failure’ stage by RIFLE
criteria, patients with BMI of 30–35 kg/m2 had the
lowest risk of death compared to those with other BMI
categories. This finding was contradicted by Danziger et
al. [6]. They found that relative risks of hospital and
l-year mortality in obese AKI group were greater than
Table 2 Baseline characteristics of patients according to disease
severity groups
Disease severity p-value
Low severity
(SOFA < 12)
High severity
(SOFA ≥12)
Number 601 543
BMI (kg/m2)a 23.4 (20.8–25.9) 23.9 (21.2–26.7) 0.009
Age (yr) 64.9 ± 14.8 61.3 ± 13.8 < 0.001
Sex (Female, %) 250 (41.6) 189 (34.8) 0.02
DM (n, %) 247 (41.2) 152 (28.0) < 0.001
HTN (n, %) 377 (62.7) 224 (41.3) < 0.001
MI (n, %) 82 (13.6) 30 (5.5) < 0.001
CHF (n, %) 136 (22.6) 50 (9.2) < 0.001
CVA (n, %) 75 (12.4) 43 (8.0) 0.04
PVD (n, %) 32 (5.3) 14 (2.6) 0.02
COPD (n, %) 49 (8.2) 31 (5.7) 0.13
Cancer (n, %)
Solid tumor 99 (16.6) 160 (29.5)
Metastasis 28 (4.7) 40 (7.4) < 0.001
Leukemia 15 (2.5) 36 (6.6)
Lymphoma 65 (10.9) 43 (7.9)
CCI score 3.0 ± 2.3 3.4 ± 2.2 0.002
Sepsis (n, %) 439 (73.0) 358 (65.9) 0.01
Postop AKI (n, %) 23 (3.8) 28 (5.2) 0.32
Cause of CRRT
Volume overload 94 (15.6) 50 (9.3)
Metabolic acidosis 126 (21.0) 118 (21.7)
Hyperkalemia 35 (5.8) 17 (3.1) 0.05
Uremia 50 (8.4) 80 (14.7)
Oliguria 165 (27.4) 118 (21.7)
Others 131 (21.9) 160 (29.5)
CRRT dose (mL/kg) 39.6 ± 12.9 45.1 ± 18.3 < 0.001
MAP (mmHg) 78.4 ± 15.0 76.4 ± 14.1 0.03
Creatinine (mg/dL) 2.6 ± 1.6 2.9 ± 1.6 0.001
eGFR (mL/min/1.73m2) 33.6 ± 23.7 29.4 ± 18.4 0.001
Albumin (g/dL) 2.6 ± 0.6 2.6 ± 0.6 0.23
Total cholesterol (mg/dL) 111.9 ± 53.3 98.7 ± 61.4 0.002
WBC (×103/mm3) 14.7 ± 14.0 13.4 ± 12.1 0.08
Hemoglobin (g/dL) 9.7 ± 2.4 9.5 ± 2.2 0.04
CRP (mg/L)a 64.8 (13.6–156.6) 75.2 (17.5–170.9) 0.12
Vasopressor (n, %) 380 (63.3) 419 (77.1) < 0.001
Ventilator (n, %) 418 (77.1) 366 (93.8) < 0.001
SOFA 9.4 ± 2.3 15.1 ± 1.9 < 0.001
APACHE II 24.6 ± 8.8 29.7 ± 7.1 < 0.001
Abbreviations: DM diabetes mellitus, HTN hypertension, MI myocardial
infarction, CHF congestive heart failure, CVA cerebrovascular attack, PVD
peripheral vascular disease, COPD chronic obstructive pulmonary disease,
CCI Charlson comorbidity index, AKI acute kidney injury, BMI body mass
index, MAP mean arterial pressure, eGFR estimated glomerular filtration
rate, WBC white blood cell, SOFA sepsis-related organ failure assessment
aData were expressed as a median and interquartile range and compared
by Mann Whitney U test
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other BMI groups. This discrepancy can partially be
explained by different disease severity between the
studies. In fact, in the study by Druml et al., the
median value of the Simplified Acute Physiology
Score II was 47 and overall ICU and hospital mortal-
ity rates were 56.1% and 63.9%. However, disease
severity was much lower in the study by Danziger et
al., where overall hospital mortality was only 10% and
baseline serum creatinine was 1.1–1.4 mg/dL without
detailed information of SOFA score. It is possible that
there is a biphasic role of obesity depending on dis-
ease severity. To corroborate this, we found that high
BMI was consistently associated with a decreased risk
of death among patients with high severity, but there
was a U-shaped pattern for mortality among those
with low severity.
It is generally accepted that fat tissue can function as
an energy reservoir. In addition, severe illness can
worsen high catabolic state, protein loss, and muscle
wasting. Thus, when disease is severe, obese patients
having high energy store can tolerate stressful and dam-
aging conditions better than non-obese patients [33]. In
contrast, energy-storage role of fat do not appear to
play a significant role in patients with low disease se-
verity. Presumably, energy-consuming process and
muscle wasting are diminished when disease burden is
less severe. The relatively well-preserved nutritional
status in patients with low disease severity can also sup-
port the findings of favourable effect between obesity
and mortality in this group. A recent study by Robinson
et al. investigated the relationship among obesity, nutri-
tional status, and mortality [19]. They showed that high
Table 3 Length of stay, survival, and mortality according to BMI classification and disease severity
Disease severity Variables BMI classification Total p-value
Underweight
(N = 99)
Normal
(N = 403)
Overweight
(N = 220)
Obesity
(N = 422)
Low ICU LOS (d)a 5 (2–14) 12 (5–26) 6.5 (3–14.5) 8 (3–15) 8 (3–18) 0.001
Hospital LOS (d)a 9.5 (2.3–44.5) 28 (14–63.5) 25.5 (10–48) 22 (9–42) 23 (10–48) 0.002
Mortality 30th day (n, %) 38 (61.3) 93 (43.5) 66 (53.2) 97 (48.5) 294 (49.0) 0.06
High ICU LOS (d)a 4 (1–12) 5 (2–14) 5 (3–18) 8 (3–18) 7 (2.5–17) 0.61
Hospital LOS (d)a 5 (2–18.5) 10 (2–27) 16 (3–37) 18.5 (6–40.8) 15 (4–35) 0.002
Mortality 30th day (n, %) 32 (86.5) 163 (86.2) 70 (72.9) 142 (64.3) 407 (74.9) < 0.001
Total ICU LOS (d)a 5 (2–14) 9 (3–20) 6 (3–15) 8 (3–16) 8 (3–17.5) 0.03
Hospital LOS (d)a 8 (2–30) 20 (7–46) 23 (6.5–45.5) 21 (8–41) 20 (6–43) 0.006
Mortality 30th day (n, %) 70 (70.7) 256 (63.5) 136 (61.8) 239 (56.8) 701 (61.3) 0.04
Abbreviations: ICU intensive care unit, LOS length of stay
aData are expressed as a median and interquartile range and compared by Kruskal-Wallis test
Table 4 Multivariable Cox regression analyses for 30-day mortality
Disease
severity
BMI
classification
Model 1 Model 2 Model 3 Model 4
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Low Underweight 1.57 (1.07–2.30) 0.02 1.66 (1.13–2.45) 0.01 1.74 (1.16–2.60) 0.007 0.99 (0.96–1.01) 0.36
Normal 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Overweight 1.44 (1.05–1.99) 0.03 1.48 (1.07–2.04) 0.02 1.41 (1.02–1.94) 0.04
Obesity 1.31 (0.98–1.76) 0.07 1.35 (1.01–1.82) 0.04 1.28 (0.95–1.72) 0.11
High Underweight 1.07 (0.73–1.56) 0.74 1.03 (0.70–1.51) 0.9 1.04 (0.70–1.53) 0.86 0.96 (0.94–0.98) < 0.001
Normal 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Overweight 0.79 (0.60–1.05) 0.11 0.81 (0.61–1.07) 0.14 0.78 (0.58–1.03) 0.08
Obesity 0.63 (0.50–0.79) < 0.001 0.64 (0.51–0.80) < 0.001 0.61 (0.48–0.76) < 0.001
Total Underweight 1.27 (0.97–1.66) 0.08 1.27 (0.97–1.67) 0.08 1.28 (0.97–1.68) 0.08 0.97 (0.96–0.99) < 0.001
Normal 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
Overweight 1.02 (0.83–1.26) 0.87 1.02 (0.83–1.27) 0.83 0.99 (0.80–1.22) 0.89
Obesity 0.84 (0.70–1.01) 0.06 0.86 (0.72–1.03) 0.1 0.81 (0.68–0.97) 0.03
Model 1: age, sex, CCI score, septic AKI, MAP, eGFR, and SOFA score
Model 2: Model 1 +WBC and albumin
Model 3: Model 2 + CRRT prescription (total effluent volume)
Model 4: Model 3 + BMI as a continuous variable
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BMI was significantly associated with survival benefit in
critical ill patients. Of note, in their findings, malnutrition
was less prevalent in obese patients than in underweight
and normal patients, suggesting nutrition as a potential
factor to explain survival advantage of obesity. Thus, when
nutritional status is poor accompanied by high disease
severity, energy-storing fat can compensate for the loss of
energy and decline in nutritional status. Conversely, better
nutritional status in low disease severity can attenuate the
favourable effects of high BMI. In this regard, future studies
should address the association between BMI, disease sever-
ity, and nutritional status in critically ill patients with AKI.
There are several limitations that should be discussed
in this study. First, to clarify the association between
BMI and mortality, we constructed various multivariable
models adjusted for many potential factors. However,
this is an observational study and unknown bias may
affect the study results and our findings need to be inter-
preted with caution. Second, only BMI was applied to
define obesity. BMI provides an easy way to measure
obesity and has been widely used. However, BMI has
been criticized because it is not an accurate measure of
fat [34]. Other parameters such as waist circumference
or abdominal diameter can be added to increase the
diagnostic accuracy for obesity [35]. Unfortunately, such
measurement was not easily feasible in the ICU setting,
particularly when patients are in critical condition.
Third, we used the BMI classification proposed by the
Committee of Clinical Practice Guidelines and Korean
Society for the Study of Obesity [23]. When the WHO
international criteria were applied, only 6.9% of patients
had BMI > 30 kg/m2 in our study. Thus, analysis for
morbid obese patients was not feasible and result of our
study may not be applicable to other ethnic groups,
whose BMI is higher than our population. We confirmed
our findings using a different flexible BMI classification
for the Asian population proposed by the WHO [24] as
indicated in Additional file 1: Table S1. Although we
defined obesity as BMI ≥ 27.5 kg/m2, the results were
unaltered. Nevertheless, we acknowledge well that BMI
Fig. 2 The relationship between BMI groups and 30-day mortality in fully adjusted Cox regression model. a low severity, b high severity
Fig. 3 The hazard ratio plot of BMI for 30-day mortality in each subgroup by fully adjusted Cox regression model. BMI was analyzed as a continuous
variable. a low severity, b high severity. Abbreviations: DM, diabetes mellitus; CVD, cardiovascular disease; BMI, body mass index
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cut-off point for obesity in this study is lower than that in
other Western countries and thus our findings may not be
extrapolated to such extremely obese patients. Further
studies with large number of obese patients should focus
on this issue. Fourth, our database did not have much in-
formation on nutritional indices, thus nutritional status
could not be thoroughly evaluated. However, all nutri-
tional supports including whether or not to start enteral
or parenteral nutrition were precisely decided by dietitians
and intensivists upon ICU admission in our centers. Fi-
nally, CRRT prescription was different across BMI and
disease severity groups. Patients with high BMI tended to
have less amount of dialysis, and this tendency was per-
sistent in both disease severity groups (data not shown).
We showed better survival of high BMI patients even with
low dose of dialysis; however, it is uncertain whether
CRRT dose can affect to mortality in AKI patients under-
going CRRT [36].
Conclusions
In conclusion, this study showed that high BMI is associ-
ated with survival benefit in AKI patients undergoing
CRRT. However, this association was observed only in
patients with high disease severity. Our findings suggest
that disease severity can modify an inverse relationship
between high BMI and mortality in these patients. Thus, in-
terpretation of this relationship should be made with
caution depending on disease severity. Further studies are
required to evaluate whether BMI can be incorporated into
risk stratification depending on disease severity in critically
ill patients.
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